Philip has more than 20 years' experience writing about companies, general finance and investing matters for a variety of publications. His career has involved spells at the Investors Chronicle, where he was small companies and companies editor, Investors Week and most recently as editor of online financial news wire Sharecast. He has also contributed to a wide range of financial-focused publications on a freelance basis.
“It’s a blended model of highly cash generative assets and top line growth”
In a study of 527 patients in China, fruquintinib slowed the disease but failed to improve survival rates
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
Clothing and accessory brands such as Alfredo Grassi, Arvind and Oakley are developing graphene-enhanced items using Directa’s G+ technology
Woodford increased its holding in hVIVO to 27.94% from 27.02%
The FDA will also review a re-labelling of another drug Turdorza for heart conditions associated with COPD
The AIM-listed drug developer has applied for approval in China in advanced colorectal cancer
The Phase Ib/II study is for people suffering from pancreatic neuroendocrine tumours (NET) and biliary tract cancer (BTC)
Redx said today it has £13.6mln in the bank, which should last it into early 2019
In a £1bn deal, won against five other tenders, Morrison's will supply Safeway products and other national brands to 1,300 McColl's stores and 350 newsagents
British Telecom is developing a habit for unpleasant surprises